Extending the preclinical development of short-term IL-15 DCs as therapeutic cancer vaccine, the aim of this study was to confirm the added value of in situ PD-L1 and PD-L2 silencing of IL-15 DCs, harnessed with a unique immune-stimulating profile that significantly outperforms IL-4 DC-mediated in vitro anti-tumor activity (7–13). Here, CD274 is linked to neoplasm.